Search results for "VIRUS"

showing 10 items of 5024 documents

Endemic hepatitis C virus infection in a Sicilian town: Further evidence for iatrogenic transmission

2002

The prevalence of and risk factors for HCV and HBV infections in the general population and the predictive value of ALT screening in identifying anti-HCV positive subjects have been evaluated in a small Sicilian town. A random 1:4 sampling from the census of the general population was performed. Anti-HCV, HCV-RNA, HCV genotype, HBsAg, and anti-HBc were tested. The linkage between HCV infection and potential risk factors was evaluated by multiple logistic regression analysis. Among 721 subjects studied, 75 (10.4%) were anti-HCV positive. The HCV infection rate increased from 0.4% in subjects 10-29 years of age to 34% in those > 60 years of age. Among the 75 anti-HCV positive subjects, 66.7% …

AdultMaleEndemic DiseasesAdolescentEpidemiologyIatrogenic DiseasePredictive Value of TestEndemic DiseaseHepacivirusAge DistributionPredictive Value of TestsRisk FactorsVirologyPrevalenceHumansChildSicilyAgedAged 80 and overHepaciviruRisk FactorGeneral populationAlanine TransaminaseHepatitis B viruHepatitis C AntibodiesMiddle AgedHepatitis BHepatitis CPopulation SurveillanceFemaleHepatitis C viruHepatitis C AntibodieHuman
researchProduct

A Common Genetic Variant inFCGR3A-V158F and Risk of Kaposi Sarcoma Herpesvirus Infection and Classic Kaposi Sarcoma

2005

Associations of FCGR3A among men with HIV/acquired immunodeficiency syndrome suggest that host responses affect the pathogenesis of Kaposi sarcoma herpesvirus (KSHV) infection and risk of acquired immunodeficiency syndrome – associated Kaposi sarcoma. Using DNA from two HIV seronegative case-control populations in Italy, we examined whether the functional FCGR3A-V158F variant was associated with risk of KSHV infection or classic Kaposi sarcoma (CKS). In population I, we examined FCGR3A variants and risk of KSHV infection in 34 KSHV latent nuclear antigen (LANA)-seropositive and 120 LANAseronegative adults from Sardinia (52% male; median age, 45 years; range, 31-60), whereas in population II…

AdultMaleEpidemiologyPopulationmedicine.disease_causeVirusHerpesviridaeAcquired immunodeficiency syndrome (AIDS)Risk FactorsOdds RatiomedicineHumansRisk factoreducationSarcoma KaposiAgedAged 80 and overeducation.field_of_studyClassic Kaposi Sarcomabusiness.industryReceptors IgGCase-control studyGenetic Variationvirus diseasesHerpesviridae InfectionsOdds ratioMiddle Agedmedicine.diseaseVirologyItalyOncologyCase-Control StudiesHerpesvirus 8 HumanImmunologybusinessCancer Epidemiology, Biomarkers & Prevention
researchProduct

Autoimmune hepatitis following Epstein-Barr virus infection

2008

We describe a case of a young man with autoimmune hepatitis (AIH) following Epstein–Barr virus (EBV) infection, in whom a long follow-up showed favourable outcome with complete clinical recovery and failure to relapse after cessation of immunosuppressive therapy. The study underlines the importance of the differential diagnosis between primary EBV associated hepatitis with features of autoimmunity, in which there is a direct pathogenetic role of the virus, and EBV related AIH, in which EBV could act as the trigger of the immune mediated damage with probable differences between the two conditions with regard to the prognosis and the responsiveness to immunosuppressive treatment. The favourab…

AdultMaleEpstein-Barr Virus InfectionsHepatitis Viral HumanAnti-Inflammatory AgentsAzathioprineDiseaseAutoimmune hepatitisSettore MED/08 - Anatomia Patologicamedicine.disease_causeMethylprednisoloneArticleVirusAutoimmunityDiagnosis Differentialimmune system diseaseshemic and lymphatic diseasesAzathioprinemedicineHumansEpstein–Barr virus infectionHepatitisbusiness.industryGeneral Medicinemedicine.diseasedigestive system diseasesHepatitis AutoimmuneLiverImmunologyDrug Therapy CombinationEBV autoimmune hepatitisDifferential diagnosisbusinessImmunosuppressive Agentsmedicine.drugCase Reports
researchProduct

Active cytomegalovirus infection is not a risk factor for Epstein-Barr virus DNAemia in the allogeneic stem cell transplantation setting

2014

AdultMaleEpstein-Barr Virus InfectionsHerpesvirus 4 HumanAdolescentCytomegalovirusReal-Time Polymerase Chain Reactionmedicine.disease_causeYoung AdultPostoperative ComplicationsRisk FactorsHumansMedicineRisk factorAgedTransplantationbusiness.industryHematopoietic Stem Cell TransplantationMiddle AgedEpstein–Barr virusVirologyTransplantationCytomegalovirus infectionCytomegalovirus InfectionsDNA ViralFemaleStem cellbusinessClinical Transplantation
researchProduct

Is Epstein-Barr virus infection associated with the pathogenesis of microscopic colitis?

2017

Abstract Background Epstein-Barr virus (EBV) has been associated with inflammation in the colon, particularly in patients with inflammatory bowel disease (IBD). Even if a relevant plasmocytosis, similar to IBD, is present in microscopic colitis (MC), the frequency of EBV infection in this setting is unknown. Objectives We aimed to compare the frequency of colonic EBV infection in patients with MC, ulcerative colitis (UC), and irritable bowel syndrome (IBS). Study design The frequency of colonic EBV infection in biopsies of 30 patients with MC, 30 patients with UC, and 30 controls with IBS was retrospectively assessed. PCR was performed to detect viral EBV DNA in colonic biopsies. In situ hy…

AdultMaleEpstein-Barr Virus InfectionsHerpesvirus 4 HumanColonBiopsymedicine.disease_causeInflammatory bowel diseasePolymerase Chain ReactionPathogenesisIrritable Bowel Syndrome03 medical and health sciences0302 clinical medicineMicroscopic colitishemic and lymphatic diseasesVirologyBiopsymedicineHumansEpstein–Barr virus infectionIrritable bowel syndromeIn Situ HybridizationAgedRetrospective Studiesmedicine.diagnostic_testbusiness.industryMiddle Agedmedicine.diseaseUlcerative colitisEpstein–Barr virusdigestive system diseasesColitis MicroscopicInfectious Diseases030220 oncology & carcinogenesisImmunologyDNA ViralRNA Viral030211 gastroenterology & hepatologyColitis UlcerativeFemalebusinessJournal of clinical virology : the official publication of the Pan American Society for Clinical Virology
researchProduct

A New Clinical and Immunovirological Score for Predicting the Risk of Late Severe Infection in Solid Organ Transplant Recipients: The CLIV Score

2020

Abstract Background We aimed at constructing a composite score based on Epstein-Barr virus DNAemia (EBVd) and simple clinical and immunological parameters to predict late severe infection (LI) beyond month 6 in solid organ transplantation (SOT) recipients. Methods Kidney and liver transplant recipients between May 2014 and August 2016 at 4 participating centers were included. Serum immunoglobulins and complement factors, peripheral blood lymphocyte subpopulations, and whole blood EBVd were determined at months 1, 3, and 6. Cox regression analyses were performed to generate a weighted score for the prediction of LI. Results Overall, 309 SOT recipients were followed-up for a median of 1000 da…

AdultMaleEpstein-Barr Virus InfectionsHerpesvirus 4 Humanmedicine.medical_specialtymedicine.medical_treatmentCD8-Positive T-LymphocytesOpportunistic Infections030230 surgeryLiver transplantationOrgan transplantationLeukocyte Count03 medical and health sciencesPostoperative Complications0302 clinical medicineInterquartile rangeInternal medicinemedicineHumansImmunology and AllergyAgedImmunosuppression TherapyReceiver operating characteristicProportional hazards modelbusiness.industryOrgan TransplantationMiddle AgedConfidence intervalTransplantationInfectious DiseasesROC CurvePeripheral blood lymphocyteDNA ViralMultivariate AnalysisFemale030211 gastroenterology & hepatologybusinessThe Journal of Infectious Diseases
researchProduct

Monitoring of Trough Plasma Ganciclovir Levels and Peripheral Blood Cytomegalovirus (CMV)-Specific CD8 + T Cells To Predict CMV DNAemia Clearance in …

2014

ABSTRACT It is uncertain whether monitoring plasma ganciclovir (GCV) levels is useful in predicting cytomegalovirus (CMV) DNAemia clearance in preemptively treated allogeneic stem cell transplant recipients. In this observational study, including 13 episodes of CMV DNAemia treated with intravenous (i.v.) GCV or oral valganciclovir, we showed that monitoring trough plasma GCV levels does not reliably predict response to therapy. Rather, immunological monitoring (pp65 and immediate-early [IE]-1-specific gamma interferon [IFN-γ]-producing CD8 + T cells) appeared to perform better for this purpose.

AdultMaleGanciclovirvirusesCongenital cytomegalovirus infectionCytomegalovirusCD8-Positive T-LymphocytesClinical TherapeuticsViral Matrix ProteinsInterferon-gammamedicineHumansValganciclovirCytotoxic T cellPharmacology (medical)GanciclovirMultiple myelomaPharmacologybusiness.industryLymphoma Non-HodgkinAnemia Aplasticvirus diseasesValganciclovirMiddle AgedPrecursor Cell Lymphoblastic Leukemia-LymphomaPhosphoproteinsmedicine.diseaseTransplant RecipientsLeukemia Myeloid AcuteLeukemiaInfectious DiseasesCytomegalovirus InfectionsDNA ViralImmunologyFemaleStem cellMultiple MyelomabusinessCD8Stem Cell Transplantationmedicine.drugAntimicrobial Agents and Chemotherapy
researchProduct

Associations of classic Kaposi sarcoma with common variants in genes that modulate host immunity

2006

AbstractClassic Kaposi sarcoma (CKS) is an inflammatory-mediated neoplasm primarily caused by Kaposi sarcoma–associated herpesvirus (KSHV). Kaposi sarcoma lesions are characterized, in part, by the presence of proinflammatory cytokines and growth factors thought to regulate KSHV replication and CKS pathogenesis. Using genomic DNA extracted from 133 CKS cases and 172 KSHV-latent nuclear antigen-positive, population-based controls in Italy without HIV infection, we examined the risk of CKS associated with 28 common genetic variants in 14 immune-modulating genes. Haplotypes were estimated for IL1A, IL1B, IL4, IL8, IL8RB, IL10, IL12A, IL13, and TNF. Compared with controls, CKS risk was decrease…

AdultMaleGenotypeEpidemiologyPopulationSingle-nucleotide polymorphismBiologySettore MED/42 - Igiene Generale E ApplicataIL12AmedicineHumansGenetic Predisposition to DiseaseRisk factoreducationSarcoma KaposiAgedAged 80 and overeducation.field_of_studyClassic Kaposi SarcomaPolymorphism GeneticCase-control studyCancerHerpesvirus InfectionOdds ratioMiddle Agedmedicine.diseaseOncologyHaplotypesItalyGenetic VariantCase-Control StudiesImmunologyHerpesvirus 8 HumanCytokinesFemaleClassic Kaposi Sarcoma
researchProduct

Liver follicular helper T-cells predict the achievement of virological response following interferon-based treatment in HCV-infected patients.

2012

Background Here, we assessed the presence of intrahepatic follicular helper T-cells (TFH) in a cohort of consecutive genotype 1 (G1) chronic hepatitis C (CHC) patients comprising non-responders (NRs), relapsers (RRs) or those with sustained virological response (SVR) to pegylated interferon and ribavirin, and tested their relation with the response to antiviral treatment. Methods A total of 78 patients with G1 CHC (30 SVR, 15 RR and 33 NR), comparable for sex, age, viral load and fibrosis were evaluated by immunohistochemistry for liver content of PD1+Bcl6+ TFH cells. The number of TFH cells in the immunostained sections was counted out of five representative high-power microscopic fields (…

AdultMaleGenotypeHepacivirusSettore MED/08 - Anatomia PatologicaAntiviral AgentsPolymorphism Single NucleotideBiomarkers PharmacologicalPolyethylene GlycolsCohort StudiesPharmacotherapyInterferonRibavirinGenotypeFollicular phaseHumansMedicinePharmacology (medical)liver biopsy Interferon-alpha follicular helper T-cellsPharmacologySettore MED/12 - Gastroenterologiabusiness.industryInterleukinsInterferon-alphaT-Lymphocytes Helper-InducerHepatitis CHepatitis C ChronicMiddle AgedViral LoadPrognosismedicine.diseaseImmunohistochemistryRecombinant ProteinsCD4 Lymphocyte CountInfectious DiseasesLiverImmunologyCohortRNA ViralImmunohistochemistryDrug Therapy CombinationFemalehcv immunohistochemistryInterferonsbusinessCohort studymedicine.drug
researchProduct

Autoregulatory role of interleukin-10 in hepatitis C patients treated with IFN-alpha.

2004

Interferon-alpha2 (IFN-alpha2) is used as standard treatment of patients with chronic hepatitis C (cHCV), but little is known about the immunomodulatory effects of this cytokine in vivo. We have studied immunologic parameters in freshly isolated peripheral blood mononuclear cells (PBMC) of 26 patients with cHCV 12 h before and 12 h after the first s.c. injection of 5-6 MU IFN-alpha2. In PBMC obtained after IFN injection, a substantial increase in IL-10 production after antigen-specific and nonspecific stimulation was observed, whereas IFN-gamma production and proliferation were significantly diminished compared with PBMC obtained before IFN injection. Patients were stratified according to s…

AdultMaleGenotypeHepacivirusmedicine.medical_treatmentImmunologyStimulationHepacivirusIn Vitro TechniquesInterferon alpha-2Peripheral blood mononuclear cellPolymorphism Single NucleotideInterferon-gammaIn vivoVirologyMedicineHomeostasisHumansInterferon gammaPromoter Regions GeneticAgedbiologyBase Sequencebusiness.industryInterferon-alphaCell BiologyHepatitis CDNAHepatitis C ChronicMiddle Agedmedicine.diseasebiology.organism_classificationRecombinant ProteinsInterleukin-10Interleukin 10CytokineImmunologyLeukocytes MononuclearFemalebusinessmedicine.drugJournal of interferoncytokine research : the official journal of the International Society for Interferon and Cytokine Research
researchProduct